The purpose of this study was to evaluate its rationality in real-world data and provide clinical evidence for the refinement of nodal CTV delineation in nasopharyngeal carcinoma(NPC).
Intensity-modulated radiation therapy (IMRT) has gradually replaced two-dimensional radiation therapy as it offers improved target conformity. Xerostomia is still the most common side effect of radiotherapy in patients with NPC treated with IMRT. Most stimulated saliva is secreted by the parotid glands (PGs), while the submandibular glands (SMGs) produce most of the unstimulated saliva and mucins, which may influence the degree of a dry mouth sensation.There are still differences in the understanding of nasopharyngeal cancer experts at home and abroad on the delineation of clinical target volumes., suitable criteria for elective irradiation of neck level Ib need to be re-evaluated.Therefore, we conducted a retrospective study to assess the feasibility of recommendation to level Ib in the International Guideline for Delineation of Clinical Target Volumes.
Study Type
OBSERVATIONAL
Enrollment
200
The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
Department of radiation oncology, Fujian cancer hospital
Fuzhou, Fujian, China
regional recurrence-free survival (RRFS)
The duration of time to regional failure were calculated from the start of treatment to the dates of recurrence.
Time frame: 60 months
level IB nodal recurrence-free survival
The duration of time to level Ib recurrence were calculated from the start of treatment to the date of Ievel Ib recurrence.
Time frame: 60 months
local recurrence-free survival (LRFS)
LRFS was calculated from the start of treatment to the dates of local recurrence.
Time frame: 60 months
distant metastasis-free survival (DMFS)
DMFS was calculated from the start of treatment to the dates of distant metastasis.
Time frame: 60 months
Overall survival
OS was calculated from the date of randomization to death from any cause.
Time frame: 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.